Content coming soon.
Back to all funds
Ye returns aapko ye sochne par majboor karte hain ki kya aapko is fund mein invest karna chahiye ya nahi.
ICICI PrudentialPharmaVery High Risk
ICICI Prudential Pharma Fund - Regular Plan - Growth
Current NAV₹77.69as of 30/5/2026
AUM4788.00 Cr
AUM
4788.00 Cr
Expense Ratio
1.95%
Min SIP
₹500
Min Lumpsum
₹1000
Launch Date
2 April 2006
Exit Load
Nil
Riskometer
LowModerateHighVery High
Risk Level: Very High
Volatility: 14.96 | Sharpe Ratio: 0.18
Fund Manager & Key Metrics
Fund ManagerAnish Tawakley(3.5 years yrs)
Volatility14.96
Sharpe Ratio0.18
Portfolio Turnover44%
BenchmarkNifty Pharma TRI
Holdings Date25/5/2026
Asset Allocation
Equity: 96.00% | T-Bills: 4.00%
Investment Objective
Aims to provide capital appreciation by investing in Pharma securities
Top Holdings
As of 25-May-2026
1. Sun Pharmaceutical Industries Ltd.20.5%
2. Dr. Reddy's Laboratories Ltd.12.8%
3. Cipla Ltd.10.4%
4. Divi's Laboratories Ltd.9.8%
5. Torrent Pharmaceuticals Ltd.7.2%
6. Aurobindo Pharma Ltd.5.8%
7. Alkem Laboratories Ltd.5.2%
8. Lupin Ltd.4.9%
9. Ipca Laboratories Ltd.3.8%
10. Mankind Pharma Ltd.3.5%
Overview
ICICI Prudential Pharma Fund - Regular Plan - Growth investment objective and strategy
ICICI Prudential Pharma Fund - Regular Plan - Growth ek equity mutual fund hai jo ki pharma sector mein invest karta hai. Iska primary objective hai long-term capital appreciation, yani ki aapke investment ko time ke saath badhana. Ye fund un investors ke liye suitable hai jo healthcare aur pharmaceuticals sector ki potential growth ke liye optimistic hain. Fund ki investment strategy sector-specific equities par focus karti hai, jo ki high growth opportunities ki taraf dhyan deti hai. Agar aap thoda risk lene ke liye tayyar hain, toh ye fund aapke portfolio ka ek achha hissa ban sakta hai.Performance & Analysis
ICICI Prudential Pharma Fund - Regular Plan - Growth historical performance and returns
ICICI Prudential Pharma Fund - Regular Plan - Growth ne pichle kuch saalon mein kaafi acha perform kiya hai. Aapko iska 1 year return 3.52% hai, jabki 3 years mein ye 9.18% aur 5 years mein 8.32% tak pohoncha hai. Is fund ka benchmark Nifty Pharma TRI hai, aur iski performance ko iske saath compare karna zaroori hai. Jab hum in returns ki baat karte hain, toh consistent growth ka pata chalta hai. Ye fund high volatility ke sath operate karta hai, lekin jab aap fund manager Anish Tawakley ki baat karte hain, unka 3.5 saal ka anubhav is fund ki performance mein ahem role play karta hai. Ye investment options se investors ko ye samajhne mein madad milti hai ki unki investments kaise perform kar rahi hain aur market ke fluctuations ka kya asar pad raha hai. Chaliye, ab benchmark return se compare karte hain:| Time Period | ICICI Prudential Pharma Fund - Regular Plan - Growth Returns | Benchmark Returns (Nifty Pharma TRI) |
|---|---|---|
| 1 Year | 3.52% | Data not available |
| 3 Years | 9.18% | Data not available |
| 5 Years | 8.32% | Data not available |
ICICI Prudential Pharma Fund - Regular Plan - Growth ke top holdings aur portfolio
ICICI Prudential Pharma Fund - Regular Plan - Growth ki top holdings mein kuch major companies hain jo pharma sector mein strong position rakhti hain. Is fund ki top 5 holdings mein Sun Pharmaceutical Industries Ltd. (20.5%), Dr. Reddy's Laboratories Ltd. (12.8%), Cipla Ltd. (10.4%), Divi's Laboratories Ltd. (9.8%), aur Torrent Pharmaceuticals Ltd. (7.2%) shamil hain. In companies ka selection fund ki investment strategy ke hisaab se bahut hi aligned hai. Ye sab leading players hain jo ki market ki demand aur supply ke hisaab se kaafi growth potential rakhte hain. Iske alawa, fund ka total AUM ₹4788 crore hai, jo ki iski popularity aur investor trust ko darshata hai. Sector allocation bhi kaafi interesting hai, kyunki pharma sector mein invest karne se aapko long-term growth potential milta hai, especially jab healthcare ki zarurat duniya bhar mein badh rahi hai. Ye fund un investors ke liye ideal hai jo portfolio diversification ke liye soch rahe hain aur high growth opportunities ko explore karna chahte hain.ICICI Prudential Pharma Fund - Regular Plan - Growth risk analysis and volatility
ICICI Prudential Pharma Fund - Regular Plan - Growth ke riskometer par iska rating 'Very High' hai. Iska matlab hai ki is fund mein invest karne wale investors ko market volatility aur price fluctuations ka samna karna pad sakta hai. Agar aap ek conservative investor hain ya risk ko avoid karna chahte hain, toh ye fund aapke liye suitable nahi hoga. Is fund ki volatility high hai, aur ye short-term mein fluctuations kar sakta hai. Isliye, agar aap long-term investing ke liye tayyar hain aur market ki ups and downs ko manage kar sakte hain, toh ye fund aapke liye suitable hai. Sharpe ratio data not available hai, lekin high risk ke sath high potential returns ko dhyan mein rakhte hue, aapko sochna chahiye ki kya aap is volatility ko handle kar sakte hain.Who Should Invest?
ICICI Prudential Pharma Fund - Regular Plan - Growth – aage kya? (long term outlook)
Aane wale samayon mein, ICICI Prudential Pharma Fund - Regular Plan - Growth ko kuch trends ka samna karna pad sakta hai. Healthcare sector historically growth dikhata aaya hai, aur ye trend aage bhi banne ki sambhavna hai. Is fund ka exposure pharma sector ke leading companies par hai, jo ki future mein health crisis aur aging population ke chalte growth ki sambhavnayein badha sakti hain. Umeed hai ki is sector ki growth se fund ko bhi fayda hoga, par exact return predictions dena mushkil hai. Updated in May 2026, aaj ke dauran investors ko long-term outlook rakhna chahiye, kyunki ye fund potential growth opportunities create karta hai. Agar aapka investment horizon kaafi lamba hai aur aap health sector ki growth ke bare mein positive hain, toh ye fund aapke liye acha option ho sakta hai.Pros & Cons
ICICI Prudential Pharma Fund - Regular Plan - Growth pros and cons for investors
- Pros:
- High growth potential in pharma sector.
- Strong historical returns over long term.
- Diversification benefits for equity mutual fund investors.
- Managed by experienced fund manager Anish Tawakley.
- Cons:
- Very high risk associated with sector volatility.
- Expense ratio of 1.95% is on the higher side.
- Short-term returns can be inconsistent.
Frequently Asked Questions
Returns
Returns
| Period | Fund Return (%) | Benchmark (Nifty Pharma TRI) (%) |
|---|---|---|
| 1 Year | 3.52% | — |
| 3 Years | 9.18% | — |
| 5 Years | 8.32% | — |
| Since Launch | 9.21% | — |
SIP Calculator
SIP / Lumpsum Calculator
Based on fund's 3Y return of 9.2%
Invested: ₹956k
Gains: ₹7697k
Total Invested
₹956245.48
Total Returns
+ ₹7696768.84
Maturity Value
₹8653014.32
SIP of ₹5000 for 10 years (stepping up 10% annually), then held for 20 years at 9.2% p.a.
*Projected returns are for illustration only. Past performance does not guarantee future returns.
Similar Funds
Related Funds in Pharma
Compare with Alternatives
Disclaimer: Mutual fund investments are subject to market risks. Please read all scheme‑related documents carefully before investing. Past performance does not guarantee future returns. The content on this page is for educational purposes only.